NAD+ vs NMN vs NR is the most searched comparison in the longevity supplement space — and for good reason. All three compounds aim to restore the cellular NAD+ pool that declines approximately 50% by age 60 across virtually every tissue studied, but they approach this goal through fundamentally different pharmacological strategies. NAD+ is the complete, active coenzyme itself. NMN (nicotinamide mononucleotide) is a direct precursor requiring one enzymatic conversion step. NR (nicotinamide riboside) is a smaller precursor requiring two conversion steps. Understanding which strategy fits your research question — direct delivery versus precursor-based restoration — determines which compound produces the most meaningful data for your specific endpoints.

PSPeptides offers NAD+ in three delivery formats — injectable vial, nasal spray, and 500mg oral tablets. For the complete NAD+ biology, see our NAD+ research guide.

The Core Distinction: Active Coenzyme vs Precursors

The NAD+ vs NMN vs NR comparison reduces to a single pharmacological question: is it better to deliver the final product directly, or to deliver a building block and let cells build the final product themselves? The answer depends on the delivery route, the target tissue, and the specific research question — there is no universally correct choice.

Understanding the age-related NAD+ decline that all three compounds aim to reverse provides essential context. Published research has documented that cellular NAD+ levels decline approximately 50% between young adulthood and age 60, driven by three converging mechanisms: increased CD38 activity (an ectoenzyme that degrades NAD+ and whose expression rises with aging-related inflammation), increased PARP consumption (as accumulated DNA damage triggers more frequent repair cycles consuming NAD+), and decreased NAMPT expression (reducing the salvage pathway’s capacity to recycle nicotinamide back into NAD+). This decline impairs mitochondrial energy production, DNA repair, sirtuin-mediated gene regulation, and cellular stress responses — contributing to multiple hallmarks of aging simultaneously. All three compounds — NAD+, NMN, and NR — aim to restore this depleted pool, but through different pharmacological strategies with different tradeoffs.

NAD+ (nicotinamide adenine dinucleotide, 663 Da): The complete, active coenzyme. When NAD+ reaches a cell in intact form, it is immediately available for use by PARPs (DNA repair), sirtuins (gene regulation), and the electron transport chain (energy production). No enzymatic conversion is needed. The challenge is delivery — NAD+’s relatively large molecular size limits oral bioavailability compared to smaller precursors. PSPeptides addresses this through multiple delivery formats: injectable (highest bioavailability), nasal spray (mucosal absorption with potential nose-to-brain delivery), and tablets (most convenient daily format).

NMN (nicotinamide mononucleotide, 334 Da): A direct NAD+ precursor requiring one enzymatic step — conversion by NMNAT (nicotinamide mononucleotide adenylyltransferase) to become NAD+. NMN is half the size of NAD+, giving it better oral absorption characteristics. Published research from the 2026 PRISMA systematic review confirms NMN supplementation increases circulating NAD+ metabolites in humans. The limiting factor is NMNAT enzyme activity, which varies between tissues, individuals, and with age — meaning the conversion efficiency from NMN to NAD+ is not constant and cannot be predicted from the dose administered alone.

NR (nicotinamide riboside, 255 Da): A smaller NAD+ precursor requiring two enzymatic steps — first conversion by NRK (nicotinamide riboside kinase) to NMN, then conversion by NMNAT to NAD+. NR’s smallest size gives it the best oral bioavailability of the three compounds, but it depends on two sequential enzymatic conversions, each with its own tissue-specific and age-dependent efficiency. NR has the most published human clinical trial data among NAD+ precursors, including studies from ChromaDex/Elysium Health clinical programs.

NAD+ vs NMN vs NR: Complete Comparison Table

The Bioavailability vs Conversion Tradeoff

The central pharmacological tradeoff in the NAD+ vs NMN vs NR comparison is bioavailability versus conversion dependency.

Smaller precursors absorb better but require conversion. NR’s 255 Da molecular weight makes it the most efficiently absorbed orally — it crosses the intestinal epithelium and enters systemic circulation with relatively high efficiency. But once inside cells, NR must undergo two enzymatic conversions (NRK → NMN → NMNAT → NAD+) before it becomes the active coenzyme. The efficiency of these conversions varies substantially: published research shows that NRK and NMNAT expression differs between tissues (liver vs muscle vs brain), between individuals (genetic variation in enzyme expression), and with age (enzyme expression declines as part of the broader metabolic aging process). This means the amount of active NAD+ that a given dose of NR ultimately produces is variable and partially unpredictable.

NAD+ is the final product but absorbs less efficiently orally. NAD+’s 663 Da molecular weight reduces its oral bioavailability — when swallowed as a tablet, a significant fraction is hydrolyzed in the GI tract before absorption. However, the portion that does reach cells intact is immediately available as the active coenzyme without any enzymatic conversion. This conversion-free delivery eliminates the variability associated with tissue-specific enzyme expression, individual genetic variation, and age-related enzyme decline.

PSPeptides addresses NAD+’s bioavailability challenge through format diversification — offering the three delivery routes that collectively eliminate every bioavailability limitation. The key insight is that NAD+’s oral bioavailability limitations do not apply to injectable or nasal delivery: subcutaneous injection bypasses the GI tract entirely, delivering intact NAD+ directly to systemic circulation with high bioavailability. Intranasal delivery provides mucosal absorption that partially bypasses first-pass hepatic metabolism, plus the unique nose-to-brain pathway for direct CNS delivery — a route that neither oral precursors nor injectable NAD+ can match for brain-targeted research. This three-format strategy means researchers are not forced to accept the bioavailability tradeoff that oral-only NMN and NR products entail — they can choose the delivery route that best matches their specific research question and endpoint. The injectable vial provides the highest systemic bioavailability (no GI degradation, no first-pass metabolism). The nasal spray provides mucosal absorption with potential nose-to-brain delivery for CNS NAD+ research. The 500mg tablets provide the most convenient daily format for extended protocols where compliance over weeks or months determines data quality.

What Does the Clinical Evidence Show?

The 2026 PRISMA-guided systematic review in Ageing Research Reviews evaluated 33 human intervention studies using NAD+-related compounds. Key findings relevant to this comparison:

Biochemical target engagement is consistent across all three compounds: Oral NR, NMN, and NAD+ supplementation all demonstrated increases in circulating NAD+ metabolites. The body can raise its NAD+ pool whether you provide the final product (NAD+), the immediate precursor (NMN), or a more distant precursor (NR).

Functional outcomes are heterogeneous regardless of compound: Effects on functional endpoints were “heterogeneous and often null or endpoint-specific” across the entire systematic review — meaning neither NAD+ nor its precursors have consistently demonstrated measurable functional improvements in every endpoint studied. This is not a failure of one compound versus another; it is a limitation of the field’s current ability to translate NAD+ elevation into consistent functional outcomes across diverse populations and endpoints. Several factors may explain this gap: study populations varied widely in age, baseline health, and likely baseline NAD+ status (those with the lowest starting NAD+ may benefit most from supplementation). Treatment durations ranged from days to months — and functional aging endpoints like vascular stiffness, cognitive decline, and body composition may require sustained NAD+ restoration over longer periods to produce detectable improvement. Dose ranges varied across studies, and the optimal dose for functional benefits may differ from the dose needed for biochemical target engagement alone. Future trials with larger sample sizes, longer durations, dose optimization, and baseline NAD+ stratification may resolve the gap between consistent biochemical engagement and variable functional outcomes — but as of 2026, this remains the central open question in human NAD+ research.

Safety is comparable: All three compounds were well-tolerated over weeks to months with no serious adverse events. Published research from clinical studies conducted at major research institutions has established that NAD+ augmentation through any of these approaches — whether through direct NAD+ delivery or precursor supplementation via NMN or NR — is safe for research applications within the dose ranges studied (typically 250-2,000mg daily for oral formats and proportionally lower for injectable and intranasal delivery routes).

Tissue-Specific Considerations: Why Route Matters

A critical but often overlooked factor in the NAD+ vs NMN vs NR comparison is tissue specificity — different tissues have different conversion enzyme expression levels, which affects how efficiently precursors are converted to active NAD+.

Liver: High NAMPT and NMNAT expression. NMN and NR are efficiently converted to NAD+ in hepatic tissue, making oral precursors effective for liver-focused NAD+ restoration. However, the liver’s first-pass metabolism also degrades a portion of all orally absorbed compounds — including the precursors themselves.

Skeletal muscle: Moderate NAMPT expression that declines with aging. Published data shows reduced NAD+ salvage pathway activity in aged muscle, potentially limiting the efficiency of precursor-to-NAD+ conversion in the tissue most relevant to sarcopenia and metabolic aging research. Direct NAD+ delivery (injectable) bypasses this conversion limitation.

Brain: The blood-brain barrier restricts entry of all three compounds from systemic circulation. NAD+ (663 Da) has limited BBB penetration. NMN’s CNS entry has been debated — published research identified a putative NMN transporter (Slc12a8) that may facilitate brain uptake, but the physiological significance remains under investigation. NR’s smaller size may allow modest BBB crossing, but brain-specific conversion enzyme activity limits its utility. PSPeptides’ NAD+ nasal spray addresses the brain delivery challenge through the nose-to-brain pathway — bypassing the BBB entirely for direct CNS NAD+ delivery. This makes the nasal spray format uniquely relevant for neurological aging research.

Heart: Cardiac tissue has high NAD+ demand (6 kg ATP daily) and published data shows cardiac NAD+ decline with age and heart failure. Both SS-31 (mitochondrial structure) and NAD+ (metabolic substrate) are relevant to cardiac bioenergetics. For cardiac-focused research, our SS-31 guide covers the complementary structural approach to cardiac mitochondrial support.

Practical Decision Framework

For researchers deciding between NAD+, NMN, and NR, the decision often comes down to three practical factors: delivery route flexibility, conversion certainty, and research endpoint.

If you need conversion-free delivery with maximum systemic bioavailability, choose NAD+ injectable. If you need potential nose-to-brain delivery for CNS research, choose NAD+ nasal spray. If you need the most convenient daily oral format, choose NAD+ tablets (500mg provides the dose range used in published human studies). If your research specifically studies NAD+ biosynthesis pathway kinetics or conversion enzyme activity, NMN or NR may be more appropriate substrates for that specific research question.

For researchers combining NAD+ restoration with other longevity interventions, the mechanistically strongest combination is NAD+ plus 5-Amino-1MQ — increasing NAD+ supply while preventing NNMT-mediated precursor waste. Adding epitalon (telomere maintenance), MOTS-C (mitochondrial signaling), and GHK-Cu (tissue regeneration) creates a multi-hallmark longevity protocol. Our longevity guide covers the complete landscape.

Choose direct NAD+ when: Your research question requires delivery of the active coenzyme without conversion variability — particularly for brain research (nasal spray with nose-to-brain delivery bypassing the BBB), controlled pharmacokinetic studies (injectable provides known systemic levels with no conversion step introducing variability), or protocols studying NAD+-dependent enzyme function (PARPs, sirtuins) where you need certainty that the active substrate is present. Also choose NAD+ when studying aged tissue where NMNAT or NRK expression may be diminished, potentially rate-limiting the precursor-to-NAD+ conversion that NMN and NR depend on. PSPeptides’ three-format availability — injectable, nasal spray, tablets — means researchers can select the delivery route matching their specific endpoint without being forced into oral-only delivery.

Consider NMN/NR when: The research question specifically studies NAD+ biosynthesis pathway kinetics, conversion enzyme activity, or the salvage pathway itself — where the conversion process is the scientific object of study rather than a pharmacological obstacle. NMN and NR also have more published clinical data specifically evaluating oral supplementation in large randomized trials.

The combination approach: The mechanistically strongest NAD+ restoration strategy combines direct NAD+ delivery (increasing supply) with 5-Amino-1MQ (inhibiting NNMT to prevent precursor degradation — reducing waste). This dual approach addresses NAD+ depletion from both sides simultaneously. Adding MOTS-C (AMPK metabolic signaling), epitalon (telomere maintenance), and GHK-Cu (tissue regeneration) creates a multi-hallmark longevity protocol. Our longevity guide and stacking guide cover protocol design.

Consider NMN/NR when: The research question prioritizes oral bioavailability above conversion-free delivery — particularly for large-scale studies where tablet convenience and absorption efficiency outweigh the conversion variability. NR and NMN have more published clinical data specifically evaluating oral supplementation endpoints.

For researchers studying NAD+ biology alongside other aging interventions, our 5-Amino-1MQ guide covers NNMT inhibition (preventing NAD+ precursor waste), our longevity guide covers the full aging peptide landscape, and our stacking guide covers principles for combining NAD+ with compounds addressing different hallmarks of aging.

Researchers should also consider the evolving regulatory landscape surrounding NAD+ precursors when planning procurement and study design. NMN classification status has been actively debated by regulatory agencies in multiple jurisdictions, and the distinction between dietary supplement and pharmaceutical classification may affect availability and research procurement pathways.

Understanding nad+ vs nmn vs nr is essential for researchers navigating this rapidly evolving field in 2026.

Frequently Asked Questions

What is the difference between NAD+, NMN, and NR?

NAD+ is the complete, active coenzyme — no enzymatic conversion needed once it reaches cells. NMN is a direct precursor requiring one enzymatic step (NMNAT enzyme) to become active NAD+. NR is a smaller precursor requiring two sequential enzymatic steps (NRK then NMNAT). The tradeoff: smaller precursors (NR, NMN) absorb better orally through the intestinal epithelium due to lower molecular weight, but they depend on conversion enzymes whose activity varies between tissues, between individuals, and declines with age. Direct NAD+ eliminates conversion variability but requires non-oral delivery formats (injectable, nasal spray) for optimal bioavailability — or accepts some GI degradation with oral tablets.

Which one raises NAD+ levels most effectively?

All three reliably raise circulating NAD+ metabolites in published human studies — the 2026 PRISMA systematic review confirmed consistent biochemical target engagement across NAD+, NMN, and NR supplementation. The difference is delivery route dependent: NR absorbs most efficiently orally due to its smallest molecular weight. But PSPeptides’ NAD+ injectable and nasal spray formats bypass oral bioavailability limitations entirely, delivering the complete active coenzyme without any GI degradation or conversion step — potentially achieving higher tissue NAD+ levels through routes that oral-only precursors cannot match.

Does PSPeptides carry NMN or NR?

PSPeptides carries direct NAD+ in three formats — injectable vial, nasal spray, and 500mg tablets — providing delivery route options that bypass the conversion dependency of NMN and NR. The direct delivery approach eliminates enzymatic conversion variability.

Can NAD+ supplementation reverse aging?

NAD+ supplementation consistently raises cellular NAD+ levels. Published rodent data shows improvements in aging markers. However, the 2026 PRISMA review found functional outcomes in humans are “heterogeneous and often null or endpoint-specific” — NAD+ elevation is reliably achieved, but consistent functional translation across all endpoints has not been demonstrated.

All PSPeptides products are sold exclusively for research and laboratory use.